All Blogs
Jun 10, 2024
The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective
Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...
Read More...
Jun 07, 2024
Dry AMD Treatment- An Underserved Market With Billion-Dollar Potential
Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...
Read More...
Jun 06, 2024
Stryker’s LIFEPAK 35 Monitor/Defibrillator; Qiagen’s QIAstat-Dx Respiratory Panel; Evolution Optiks’s 510(k) Clearance; Microbot Medical Endovascular Surgical Robot Trial; Nexalin’s Insomnia and Anxiety Therapy Headset Clinical Trial; KORU Medical Systems’ Study With Commercialized Oncology Biologics
Stryker Released LIFEPAK 35 Monitor/Defibrillator On June 04, 2024, Stryker, a global leader in medical technologies, announced the launch of the LIFEPAK 35 monitor/defibrillator. This latest addition to their monitor/defibrillator lineup features advanced technology and is designed on an intuitive, modern...
Read More...
Oct 28, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Wireless brain sensors are emerging as a transformative technology in neuroscience and healthcare, offering a new level of precision, comfort, and real-time monitoring for patients with neurological conditions. Unlike traditional wired sensors that limit mobility and can cause discomfort, wireless brain sensors use...
Read More...
Jun 04, 2024
Moderna’s mRESVIA(R) FDA Approval; Novartis Scemblix® Phase III Data; Kite’s Tecartus for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Astellas’ Zolbetuximab Biologics License Application; CHMP Recommends AstraZeneca’s Tagrisso
FDA Greenlights Moderna's RSV Vaccine mRESVIA(R) Moderna, Inc. has announced that the FDA has approved mRESVIA (mRNA-1345), an mRNA-based vaccine for respiratory syncytial virus (RSV), to protect adults aged 60 and over from lower respiratory tract infections caused by RSV. This approval, granted under a breakth...
Read More...
Jun 03, 2024
Rapid Global Expansion of Chinese PD-1/PD-L1 Key Players
Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US an...
Read More...
May 31, 2024
The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs
The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...
Read More...
May 30, 2024
Solis Mammography’s Acquisition of MUSIC Imaging Center; Nikon’s SI-PH Phase Condenser Accessory Option; Teijin Launch Surgical Patch; Terumo Cardiovascular’s FDA 510(K) Clearance; Spineart’s 510(k) Clearance; Ceretrieve’s Success in FIH Ischemic Stroke Cases
Solis Mammography Announced Acquisition of MUSIC Imaging Center in Gainesville, Florida On May 28, 2024, Solis Mammography announced the acquisition of the MUSIC Mammography and Ultrasound Imaging Center in Gainesville, Florida. For more than 10 years, MUSIC has provided patients with an advanced standard ...
Read More...
May 29, 2024
From Lab to Lifesaver: Advancing Artificial Blood Vessels for Healthier Tomorrows
Artificial blood vessels are at the forefront of medical innovation, offering a lifeline to millions worldwide. With advancements in bioengineering, these synthetic conduits are shaping a new era in healthcare, promising solutions to cardiovascular diseases and beyond. Artificial blood vessels represent a revolu...
Read More...
May 28, 2024
AstraZeneca’s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen’s LEQEMBI South Korea Approval; AltruBio’s $225M Series B Funding; GSK’s Depemokimab Positive Phase III Severe Asthma Results; Roche’s Inavolisib FDA Breakthrough Therapy Designation
The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint o...
Read More...